Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Abrari, Andleeb"'
Publikováno v:
Oncology Journal of India. Jan-Mar2024, Vol. 8 Issue 1, p16-19. 4p.
Publikováno v:
Journal of Cancer Research & Therapeutics. Mar2023, Vol. 19 Issue 2, p480-483. 4p.
Publikováno v:
Indian Journal of Pathology & Microbiology. Jul-Sep2023, Vol. 66 Issue 3, p664-666. 3p.
Autor:
Tyagi, Aarti1 (AUTHOR), Abrari, Andleeb2 (AUTHOR), Khurana, Anuj2 (AUTHOR), Tyagi, Shantanu3 (AUTHOR)
Publikováno v:
Journal of Cancer Research & Therapeutics. Jul-Sep2022, Vol. 18 Issue 4, p1129-1136. 8p.
Publikováno v:
Cancer Research, Statistics & Treatment. Oct-Dec2022, Vol. 5 Issue 4, p754-756. 3p.
Autor:
Abrari, Andleeb1 (AUTHOR), Shehwar, Durre2 (AUTHOR), Hussain, Bilal3 (AUTHOR), Akhtar, Kafil2 (AUTHOR)
Publikováno v:
Oncology Journal of India. May-Aug2022, Vol. 6 Issue 2, p56-58. 3p.
Publikováno v:
Journal of Cancer Research & Therapeutics. Jan-Mar2021, Vol. 17 Issue 1, p288-290. 3p.
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 51, Iss 3, Pp 457-458 (2008)
Externí odkaz:
https://doaj.org/article/827bf898d4644390982c142020394897
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 212 (2012)
Abstract Background KIT is a proto-oncogene involved in diverse neoplastic processes. Aberrant kinase activity of the KIT receptor has been targeted by tyrosine kinase inhibitor (TKI) therapy in different neoplasias. In all the earlier studies, KIT e
Externí odkaz:
https://doaj.org/article/4fe54abda5c74d2a8b63e944d637498d
Publikováno v:
Annals of Oncology Research & Therapy; Jan-Jun2022, Vol. 2 Issue 1, p35-37, 3p